by cristiano | Oct 17, 2018
Only in the case where the geneticist recognizes a reproductive risk for a specific monogenic disease, the genetic test for that single disease should be performed on the component at risk. Whether a monogenic autosomal recessive disease is present, the test should be...
by cristiano | Oct 17, 2018
The public may be misled about the real benefit of these tests and it is often not aware of the limitations of the test. Without consulting a geneticist is also difficult to interpret correctly the test result. Finally, it is found that those who undergo the tests...
by cristiano | Oct 17, 2018
Since the risk of developing thrombotic events is conferred by the presence of hyperhomocysteinemia, it is considered more useful and valid, from the clinically point of view, consider the value of plasma homocysteine, which is also influenced by several other...
by cristiano | Oct 17, 2018
Based on the most recent literature assessing the effectiveness of bevacizumab, the benefit expected from this agent for its various oncologic indications is in the order of a few weeks of survival gained. Since the cost of bevacizumab is high and its incremental...
by cristiano | Oct 17, 2018
The recent development of bioresorbable coronary stents (Bioresorbable Vascular Scaffolds, BVS) represent a promising therapeutic option as compared with traditional drug-eluting stents (DES). However, based on the most recent evidence currently available, BVS (the...
Recent Comments